PURPOSE: We report CNS efficacy of first-line osimertinib plus chemotherapy versus osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) from the phase III FLAURA2 study according to baseline CNS metastasis status. METHODS: Patients were randomly assigned to osimertinib plus platinum-pemetrexed (combination) or osimertinib monotherapy until disease progression or discontinuation. Brain scans were performed in all patients at baseline and progression and at scheduled assessments until progression for patients with baseline CNS metastases; scans were assessed by neuroradiologist CNS blinded independent central review (BICR). RESULTS: On the basis of baseline CNS BICR, 118 of 279 (combination) and 104 of 278 (monotherapy) randomly assigned patients had ≥one measurable and/or nonmeasurable CNS lesion and were included in the CNS full analysis set (cFAS); 40 of 118 and 38 of 104 had ≥one measurable target CNS lesion and were included in the post hoc CNS evaluable-for-response set (cEFR). In the cFAS, the hazard ratio (HR) for CNS progression or death was 0.58 (95% CI, 0.33 to 1.01). In patients without baseline CNS metastases, the HR for CNS progression or death was 0.67 (95% CI, 0.43 to 1.04). In the cFAS, CNS objective response rates (ORRs; 95% CI) were 73% (combination; 64 to 81) versus 69% (monotherapy; 59 to 78); 59% versus 43% had CNS complete response (CR). In the cEFR, CNS ORRs (95% CI) were 88% (73 to 96) versus 87% (72 to 96); 48% versus 16% had CNS CR. CONCLUSION: Osimertinib plus platinum-pemetrexed demonstrated improved CNS efficacy compared with osimertinib monotherapy, including delaying CNS progression, irrespective of baseline CNS metastasis status. These data support this combination as a new first-line treatment for patients with EGFR-mutated advanced NSCLC, including those with CNS metastases.

1st Faculty of Medicine Charles University Thomayer Hospital Prague Czech Republic

Department of Clinical Oncology Rondebosch Oncology Centre Cape Town South Africa

Department of Internal Medicine Prince of Songkla University Songkhla Thailand

Department of Life Sciences National Chung Hsing University Taichung Taiwan

Department of Medical Oncology and Hematology University Health Network Princess Margaret Cancer Centre Toronto ON Canada

Department of Medical Oncology Cancer Care Centre St George Hospital Kogarah NSW Australia

Department of Medical Oncology Harbin Medical University Cancer Hospital Harbin China

Department of Medical Oncology Lowe Center for Thoracic Oncology Dana Farber Cancer Institute Boston MA

Department of Medical Oncology Thoracic Group and International Center for Thoracic Cancers Gustave Roussy Villejuif France

Department of Oncology Biometrics AstraZeneca Cambridge United Kingdom

Department of Oncology Instituto Nacional de Enfermedades Neoplasicas Lima Peru

Department of Oncology National Taiwan University Hospital and National Taiwan University Cancer Center National Taiwan University Taipei Taiwan

Department of Respiratory Medicine Saitama Medical University International Medical Center Hidaka Japan

Department of Respiratory Medicine Shanghai Chest Hospital Shanghai Jiao Tong University Shanghai China

Department of Thoracic Oncology Jilin Cancer Hospital Changchun China

Department of Thoracic Oncology Kanagawa Cancer Center Yokohama Japan

Division of Chest Medicine Department of Internal Medicine Taichung Veterans General Hospital Taichung Taiwan

Division of Oncology Department of Internal Medicine Faculty of Medicine Chiang Mai University Chiang Mai Thailand

Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan

Faculty of Medicine Paris Saclay University Paris France

Federal State Budgetary Institution N N Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation Moscow Russia

Late Development Oncology AstraZeneca Cambridge United Kingdom

Late Development Oncology AstraZeneca Gaithersburg MD

Medical Oncology Department Bradford Hill Clinical Research Center Santiago Chile

Research Institute for Diseases of the Chest Graduate School of Medical Sciences Kyushu University Fukuoka Japan

Zobrazit více v PubMed

Peters S, Bexelius C, Munk V, et al. : The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev 45:139-162, 2016 PubMed

Popat S, Ahn MJ, Ekman S, et al. : Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases: Current evidence and future perspectives on therapeutic strategies. Target Oncol 18:9-24, 2023 PubMed

Rangachari D, Yamaguchi N, VanderLaan PA, et al. : Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer 88:108-111, 2015 PubMed PMC

Cho BC, Han JY, Kim SW, et al. : A phase 1/2 study of lazertinib 240 mg in patients with advanced EGFR T790M-positive NSCLC after previous EGFR tyrosine kinase inhibitors. J Thorac Oncol 17:558-567, 2022 PubMed

Saito R, Sugawara S, Ko R, et al. : Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL study. Eur J Cancer 185:83-93, 2023 PubMed

Schoenmaekers J, Paats MS, Dingemans AMC, et al. : Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: How to treat and when? Transl Lung Cancer Res 9:2599-2617, 2020 PubMed PMC

Le Rhun E, Guckenberger M, Smits M, et al. : EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Ann Oncol 32:1332-1347, 2021 PubMed

Vogelbaum MA, Brown PD, Messersmith H, et al. : Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol 40:492-516, 2022 PubMed

Passaro A, Leighl N, Blackhall F, et al. : ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol 33:466-487, 2022 PubMed

Cross DA, Ashton SE, Ghiorghiu S, et al. : AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4:1046-1061, 2014 PubMed PMC

Mok TS, Wu YL, Ahn MJ, et al. : Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629-640, 2017 PubMed PMC

Soria JC, Ohe Y, Vansteenkiste J, et al. : Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113-125, 2018 PubMed

Wu Y-L, Tsuboi M, He J, et al. : Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med 383:1711-1723, 2020 PubMed

Wu Y-L, Ahn MJ, Garassino MC, et al. : CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: Data from a randomized phase III trial (AURA3). J Clin Oncol 36:2702-2709, 2018 PubMed

Reungwetwattana T, Nakagawa K, Cho BC, et al. : CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol 36:3290-3297, 2018 PubMed

Ramalingam SS, Vansteenkiste J, Planchard D, et al. : Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 382:41-50, 2020 PubMed

Papadimitrakopoulou VA, Mok TS, Han JY, et al. : Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol 31:1536-1544, 2020 PubMed

Ahn MJ, Chiu CH, Cheng Y, et al. : Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: The AURA leptomeningeal metastases analysis. J Thorac Oncol 15:637-648, 2020 PubMed

Yang JCH, Kim SW, Kim DW, et al. : Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study. J Clin Oncol 38:538-547, 2020 PubMed PMC

Tsuboi M, Herbst RS, John T, et al. : Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med 389:137-147, 2023 PubMed

Goss G, Tsai CM, Shepherd FA, et al. : CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Pooled data from two phase II trials. Ann Oncol 29:687-693, 2018 PubMed

Hosomi Y, Morita S, Sugawara S, et al. : Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol 38:115-123, 2020 PubMed

Noronha V, Patil VM, Joshi A, et al. : Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J Clin Oncol 38:124-136, 2020 PubMed

Hou X, Li M, Wu G, et al. : Gefitinib plus chemotherapy vs gefitinib alone in untreated EGFR-mutant non-small cell lung cancer in patients with brain metastases: The GAP BRAIN open-label, randomized, multicenter, phase 3 study. JAMA Netw Open 6:e2255050, 2023 PubMed PMC

Planchard D, Jänne PA, Cheng Y, et al. : Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med 389:1935-1948, 2023 PubMed

Fink KR, Fink JR: Imaging of brain metastases. Surg Neurol Int 4:S209-S219, 2013. (suppl 4) PubMed PMC

Ballard P, Yates JW, Yang Z, et al. : Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 22:5130-5140, 2016 PubMed

Colclough N, Chen K, Johnström P, et al. : Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin Cancer Res 27:189-201, 2021 PubMed

Jacobs SS, Fox E, Dennie C, et al. : Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin Cancer Res 11:1669-1674, 2005 PubMed

Kumthekar P, Grimm SA, Avram MJ, et al. : Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. J Neurooncol 112:247-255, 2013 PubMed

Barlesi F, Gervais R, Lena H, et al. : Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: A multicenter phase II trial (GFPC 07-01). Ann Oncol 22:2466-2470, 2011 PubMed

Yu X, Fan Y: Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status. Medicine (Baltimore) 98:e14110, 2019 PubMed PMC

Varrone A, Varnäs K, Jucaite A, et al. : A PET study in healthy subjects of brain exposure of (11)C-labelled osimertinib—A drug intended for treatment of brain metastases in non-small cell lung cancer. J Cereb Blood Flow Metab 40:799-807, 2020 PubMed PMC

Ekman S, Cselényi Z, Varrone A, et al. : Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study. Clin Transl Sci 16:955-965, 2023 PubMed PMC

Herbst RS, Wu YL, John T, et al. : Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: Updated results from the phase III randomized ADAURA trial. J Clin Oncol 41:1830-1840, 2023 PubMed PMC

Monaco EA, III, Faraji AH, Berkowitz O, et al. : Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer. Cancer 119:226-232, 2013 PubMed

Parsons MW, Peters KB, Floyd SR, et al. : Preservation of neurocognitive function in the treatment of brain metastases. Neurooncol Adv 3:v96-v107, 2021. (suppl 5) PubMed PMC

Hendriks LE, Kerr KM, Menis J, et al. : Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:339-357, 2023 PubMed

Zobrazit více v PubMed

ClinicalTrials.gov
NCT04035486